<SEC-DOCUMENT>0001104659-16-136699.txt : 20160804
<SEC-HEADER>0001104659-16-136699.hdr.sgml : 20160804
<ACCEPTANCE-DATETIME>20160803202651
ACCESSION NUMBER:		0001104659-16-136699
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160803
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160804
DATE AS OF CHANGE:		20160803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		161805428

	BUSINESS ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a16-16154_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES </font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> August&nbsp;3, 2016</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">101 Park Drive, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\16-16154-1\task8049794\16154-1-ba.htm',USER='105537',CD='Aug  4 04:41 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;7.01 </font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Events.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On August&nbsp;3, 2016, Adaptimmune Therapeutics plc (the &#147;Company&#148;) </font>issued a press release reporting a partial clinical hold </font>on its planned pivotal study of NY-ESO SPEAR<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;T-cell therapy in myxoid round cell liposarcoma.&#160; This trial is not yet active at any investigational sites, and has not recruited any patients. This notification of partial clinical hold from the U.S. Food and Drug Administration (FDA) does not apply to any other Adaptimmune study. The Company intends to provide a full response to the FDA shortly and will discuss the partial clinical hold during its conference call to discuss the second quarter ended June&nbsp;30, 2016, scheduled for 8:00 am Eastern Time (1:00 pm BST) on Monday August&nbsp;8, 2016. The press release is furnished as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K and is incorporated by reference herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information in Item&nbsp;7.01 of this Form&nbsp;8-K (including Exhibit&nbsp;99.1) shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered &#147;filed&#148; or incorporated by reference therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.&#160; The following exhibit is furnished as part of this Report on Form&nbsp;8-K:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:37.35pt;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   August&nbsp;3, 2016.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_040716_2265"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105537\16-16154-1\task8049794\16154-1-ba.htm',USER='105537',CD='Aug  4 04:41 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;3,   2016</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_040834_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105537\16-16154-1\task8049794\16154-1-ba.htm',USER='105537',CD='Aug  4 04:41 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;Index</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   August&nbsp;3, 2016</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_040908_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105537\16-16154-1\task8049794\16154-1-ba.htm',USER='105537',CD='Aug  4 04:41 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a16-16154_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="343" height="67" src="g161541mmi001.gif"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">&#174;</font></b><b>&#160;T-cell Therapy in Myxoid Round Cell Liposarcoma</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, UK, August&nbsp;3, 2016 &#151; Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patients. This notification of partial clinical hold does not apply to any other Adaptimmune study.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA notification is not based on safety concerns. In its correspondence, the FDA requested additional CMC information and answers to certain trial design questions prior to the trial start. Adaptimmune intends to provide a full response to the FDA shortly.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Adaptimmune is running a number of different studies with its NY-ESO program and continues to enroll patients in synovial sarcoma, ovarian, and lung cancer trials in the U.S.,&#148; said James Noble, Adaptimmune CEO. &#147;We have been in dialogue with the FDA since achieving breakthrough status earlier this year and this partial clinical hold requires a number of questions to be answered before we can start a new MRCLS trial intended to be used for registration purposes. We will be providing a full response to the FDA shortly and will update the markets when we have further news to report.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The company will discuss this notice of partial clinical hold during its conference call to discuss the second quarter ended June&nbsp;30, 2016, scheduled for </font>8:00&nbsp;a.m.&nbsp;Eastern Time (1:00 p.m.&nbsp;BST) on Monday August&nbsp;8, 2016.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR</font><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">&#174;</font></b>&#160;(Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body&#146;s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune&#146;s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\16-16154-1\task8049886\16154-1-mm.htm',USER='105538',CD='Aug  4 05:37 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). </font>These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form&nbsp;10-Q filed with the Securities and Exchange Commission (SEC) on May&nbsp;12, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 825-9306</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\16-16154-1\task8049886\16154-1-mm.htm',USER='105538',CD='Aug  4 05:37 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g161541mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g161541mmi001.gif
M1TE&.#=A5P%# '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    5P%# (?___]*8ZUC<[7O]_?6UN^U&2E:8[6MM=;FK:WOWM[>>X24G,Z$
MC+USA+WF:V/F[^][E,Z]UM[.UMX0.N80$.:]K1"]YA"]<Q!S:ZWFI93FM<76
M8VO%&2D0K:406C$0WC$0&3$0G#$0:V,0[V,0*6,0K6-"SJ5"C*40SJ40C*40
M2F,0SF,0"&,0C&/OSM;_]_>]0F,08YP08\[_YN^]O>:],3%".N:4.N9K.N9"
M$.:4$.9K$.:]:U)SQ>9S[^;OK1#OYA#O<Q"]&4KFA*7FWN^48YQ"[^9"K>80
M[^80K>:]K3&]YC&]<S&]M6.]4N^]YG.]4JV]YK6]&>^]&:U"SN9"C.80SN80
MC.:]E&.]4LZ]YE*]4HR]YI2]&<Z]&8S%0DJUG-Z4O=Z,2F-K2F.4:V.4[V-"
M:V-"[V-"6C%"WC&46C&4WC%"&3%"G#&4&3&4G#%"*6-"K6.4*6.4[Z64K6-K
M6C%KWC%K&3%KG#&4Q:5K:V-K[V-K*6-KK6.]>]Z4SF-"2F-"SF-""&-"C&.4
M"&.4C&-KSF-K"&-KC&.<K<[FM>^4E)R].A!"8\XQ8YR]K:USE._FA.\08^_F
M$&OF$"EKE)R]K8SFA,[F$$KF$ B]WN^4[^;OM6/O4N_OYG/OK3'O4JWOYC'O
M<S'OYK7O&>_O&:V]&6OOE&/O4L[OYE+O4HSOYI3O&<[O&8QSC+WF0FN]$!"]
MO=:]A*V]>XR48^]"8^_F0BD0.K5K8^\0$+40:Q 0[Q 0*1 0K1#F0DJ48\[F
M0@@0.I1K8\X0$)002A 0SA 0"! 0C!!*6K5*:ZU".K64.K5K.K5"$+64$+5K
M$+5":Q!"[Q"4:Q"4[Q!"*1!"K1"4*1"4K1!S[[5K:Q!K[Q!K*1!KK1!SQ;5"
M.I24.I1K.I1"$)24$)1K$)1"2A!"SA"42A"4SA!""!!"C!"4"!"4C!!S[Y1K
M2A!KSA!K"!!KC!!SQ91"[[5"K;40[[5"[Y1"K900[Y1:8YR<E.:]:W/6YN^U
M"#%*6I3__^]*4JT(_P !"!Q(L*#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LN3 !QYGS##)LJ7+ES!C5AQP $(B(AM=*-"'8*7,GT"#"ATJ
M<0"!!1C^&6 08<#%! @V?.'P18$&GT2S:MW*5>2 6 T"B!7;  Q*BBZ&?"E0
M@$.!&AMZ=IU+MZ[=A/X(0 CP;ZQ8 3<E^M.YEH-;PP4V7+W+N+'CH$83,1#;
MUT#?  N(.'VH84/;PS6H;LC@PM_CTZA3CR222  &OV(S/W2Q@4.-MC7X?8&A
MP,4+U<"#"W_XX,%F@2]H-'@=@#E@G P3>#9\^(MBK  >), ^O+OWQU\7'/\@
M<#S[ @-\*0<(K'"&5+<%IE9-8%K@# T9%,C]SK__W*_"D!6+9@,-T!IL AQ0
M7D$S9,#68?'M!\ ,A/$3GP;U^:?AAC(-0,0"8U5&P%D O-#:/\P%T,"("&DP
M55M"4+7?# \@\,5MB&W@ H<\]FC2 XF$Z%<B _P&P  +")!>7PN0.) _1+Q8
MV!<2ZH2C;6U5Q5U6 SQ A'$^AJD5 6%=EN(_F1F)I%C,&:!@0?ZHU=:<0R1@
M'VV&Q5A C&Y]86=%Q7WII$9D&B! + O6-4"78JKV0"P,,-?79?] <-8+1$SF
MEVP%NE"86W#]"8"+M[WUEFW6(6#D1"^<%X !Y'7_%$$#_S1  Y>K'L1: P=
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MDEHO9#G:#5EHX ;>U7L/H $,&VC&;#?0V@A 0 ;"O2H-B#O<"(#.?= ];OI
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MTT4^6\EZN7?-OV?QN1=^X_,O>K40X!(T^=!VFS8WI.9I(<902P%WI%9_#HA
M9-<])0(WP*00K[9TQ"<QR9 (%446)W<_E-5WS>$*3%<R?<$ ]X0>'&0Y>#,Q
MP&<\3\,73+)U$7 Q?8$,508 GH91<E  %F(AV>(/:]$6NK$8_P(?7)56*'>#
MP49[E0=PI^0YN8<0A:)Y6G9@!_4/E[$T#.!3"K)@&+ B#8%K > *1Z-QJH=
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M:]9X0)$!6+?# #V$DNV93]ZXGZ2,4#%T=E%E?\FQ+CQ)/JZ0M0_,GZ7Z<Q)
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M]],@!NX/_BX5*8X5S5+SG#XV"E$?GP_H-F+JHK_\\^XDXA0AV"'@ED\E  %
M(( !&SA\^:(@P4"!&C9L(,)0XD2*%2U>Q)BQ8H8-+F8,])=@@P($7S)\'%@2
MH9 -"% "<*$@@XL-0C0P=)%! P*2"P&\<*$/P8.)-%N65#@P 4>>'1F*)(D
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B^13TQ#P::RLT44479;111Q^%-%)))Z6T4DLOQ331@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
